| Annual · values | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | — | — | — | — | — | — | — | — | 60.81% | 94.05% | 88.95% | 65.28% |
| Operating Margin | -3.35% | -72.92% | -97.58% | -179.09% | -466.06% | -414.37% | -343.14% | -395.48% | -1690.65% | -370.96% | -431.80% | -1989.55% |
| EBITDA Margin | -1.96% | -70.44% | -94.27% | -174.03% | -459.73% | -409.78% | -338.65% | -390.24% | -1664.47% | -364.55% | -424.70% | -1966.78% |
| Net Margin | 98.54% | -87.63% | -96.11% | 1698.54% | -360.55% | -386.90% | -322.08% | -357.01% | -1854.97% | -391.94% | -432.56% | -2028.05% |
| Current Ratio | 10.93 | 5.02 | 5.39 | 12.31 | 4.26 | 3.18 | 3.03 | 5.41 | 6.05 | 10.73 | 4.80 | 6.67 |
| Quick Ratio | 10.93 | 5.02 | 5.39 | 12.31 | 4.26 | 3.18 | 3.03 | 5.41 | 5.79 | 10.48 | 4.60 | 6.37 |
| Debt / Equity | — | — | 0.00 | — | -1.82 | -2.04 | -2.03 | -8.81 | 1.94 | — | — | — |
| ROE | 35.69% | -32.14% | -25.91% | 197.40% | 58.90% | 91.53% | 105.64% | 417.77% | -247.79% | -54.44% | -74.97% | -81.80% |
| ROA | 21.81% | -15.93% | -14.45% | 143.58% | -53.21% | -59.27% | -57.84% | -38.47% | -64.66% | -29.83% | -60.72% | -70.18% |
| Asset Turnover | 0.22 | 0.18 | 0.15 | 0.08 | 0.15 | 0.15 | 0.18 | 0.11 | 0.03 | 0.08 | 0.14 | 0.03 |
| Book Value / Share | 5.76 | 3.59 | 3.85 | 6.00 | -4.87 | -4.87 | -4.03 | -0.96 | 2.20 | 7.83 | 7.12 | 9.13 |
Theravance Biopharma is a biopharmaceutical company focused on discovering, developing, and commercializing small-molecule medicines targeting respiratory disease, inflammatory and immunology conditions, and rare disorders. The company's flagship product, YUPELRI (revefenacin), is an FDA-approved once-daily, nebulized long-acting muscarinic antagonist for chronic obstructive pulmonary disease (COPD) maintenance treatment. Beyond its established respiratory franchise, Theravance Biopharma maintains a diversified clinical pipeline including ampreloxetine, a norepinephrine reuptake inhibitor in late-stage development for symptomatic neurogenic orthostatic hypotension, and a gut-selective pan-JAK inhibitor being evaluated for inflammatory bowel diseases. The company leverages internal research capabilities alongside strategic partnerships and collaborations to advance its candidates through clinical and regulatory milestones. Headquartered in South San Francisco, California, with corporate offices in Dublin, Ireland, Theravance Biopharma operates research facilities in the Bay Area supporting its global clinical programs and commercialization efforts.